Tech Company Financing Transactions
Cascade Pharmaceuticals Funding Round
Cascade Pharmaceuticals closed a $72 million funding round on 2/12/2026. Investors included China Life Insurance, Gaorong Capital and QingSong Fund.
Transaction Overview
Company Name
Announced On
2/12/2026
Transaction Type
Venture Equity
Amount
$72,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Building 6, Lane 908, Ziping Road, Pudong New Area
Shanghai, Undisclosed
China
Shanghai, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Cascade Pharmaceuticals is a clinical-stage biopharmaceutical company established on December 26, 2017. Focused on addressing unmet medical needs in metabolic diseases and inflammation, the company specializes in the discovery, development, and commercialization of innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs). Guided by its mission, "Curing diseases, enabling healthier lives," Cascade strives to be a global leader in next-generation drug development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eric Xu
Browse more venture capital transactions:
Prev: 2/12/2026: Electric Twin venture capital transaction
Next: 2/12/2026: OncoRes Medical venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs